RxDoctor Payments Data

Chadi Hage, MD

Pulmonary Disease · Pittsburgh, PANPI 1780649236

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $9,200 of the $11,664 with a category attached, or 78.9%. Diasorin Molecular LLC accounts for 78.9% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $9,310 and has fallen 92.2% since, to $728 in 2025.

$11,664in general payments, 2019–2025

Across 20 payments — averaging $583.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Diasorin Molecular LLC$9K
  • Transmedics, Inc.$728
  • Livanova USA, Inc.$556
  • Exelixis Inc.$311
  • Abiomed$277
  • La Jolla Pharmaceutical Company$268
  • plus $324 from 3 others
$467,493in research payments, 2019–2025

Across 29 payments — averaging $16,120 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Incyte Corporation$312K
  • Astellas Pharma Global Development$150K
  • Xvivo Perfusion Inc.$6K

What the payments were for

  • Consulting fees$9,20079%
  • Travel & lodging$7286%
  • Food & beverage$1,59514%
  • Education$1411%

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,664 in reported general payments places this provider in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

See all pulmonary disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$41,754
Medicare patients
64
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CresembaIsavuconazonium Sulfate11$72,062
Everolimus28$69,455
EliquisApixaban32$38,108
Tacrolimus79$28,602
ZarxioFilgrastim-Sndz22$19,157
Atovaquone34$18,424
Posaconazole13$16,205
Valganciclovir Hcl35$13,624
LokelmaSodium Zirconium Cyclosilicate12$9,748
Mycophenolate Mofetil22$7,297
Cyclosporine ModifiedCyclosporine, Modified19$6,881
Voriconazole17$6,787
Azithromycin172$2,914
Pantoprazole Sodium128$2,837
Lansoprazole16$2,675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$121$9,74812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 703 pulmonary disease providers in Pennsylvania.

Other pulmonary disease in Pittsburgh

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →